



Financial Tear Sheet

Corporate Profile

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD's first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Additional clinical trials of Iclusig in other cancers are ongoing. ARIAD is also studying AP26113, another molecularly targeted medicine, in certain forms of lung cancer.

Primary IR Contact

Manmeet Soni
Chief Financial Officer
ARIAD Pharmaceuticals,
Inc.

Phone: 617-503-7298

E-mail:


manmeet.soni@ariad.com

Stock Performance

Exchange	NASDAQ (US Dollar)
Price	\$23.99
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$4.67
Market Cap	\$4,658,878,679
Rolling EPS	-0.18
PE Ratio	0

Shares Outstanding 194,200,862

Data as of 02/15/17 4:15 p.m. ET



Recent Headlines & Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 3.0



Sell

Strong Buy

Unable to fulfill request.

SEC Filings

Filing Date	Form
04/07/17	SC 13G/A
02/27/17	CT ORDER
02/27/17	15-12B
02/21/17	SC 13D/A

Corporate Governance

Harvey J. Berger, M.D.	Chairman and Chief Executive Officer
David Berstein, Esq.	Senior Vice President and Chief Intellectual Property Officer
Daniel M. Bollag, Ph.D.	Senior Vice President of Regulatory Affairs and Quality
Joseph Bratica	Vice President, Finance and Controller
Maria E. Cantor	Senior Vice President, Corporate Affairs
Timothy P. Clackson, Ph.D.	President of Research and Development and Chief Scientific Officer
David C. Dalgarno, Ph.D.	Vice President, Research Technologies
Jonathan E. Dickinson	Vice President, European Operations

and General Manager,
ARIAD
Pharmaceuticals
(Europe), Sarl

[Pierre F. Dodion, M.D., M.B.A](#) Senior Vice President,
Corporate
Development and
Operations

[Martin J. Duvall](#) Senior Vice President,
Commercial
Operations

[Edward M. Fitzgerald](#) Executive Vice
President, Chief
Financial Officer and
Treasurer

[Frank G. Haluska, M.D., Ph.D.](#) Chief Medical Officer
and Senior Vice
President, Clinical
R&D

[Shirish Hirani, Ph.D.](#) Vice President,
Program and Alliance
Management

[Stephen R. Jamieson](#) Vice President,
Information
Technology

[Raymond T. Keane, Esq.](#) Senior Vice President,
General Counsel,
Secretary and Chief
Compliance Officer

[Ronald K. Knickerbocker, Ph.D.](#) Vice President,
Biomedical Data
Sciences and
Information

[Jing L. Marantz, M.D., Ph.D.](#) Vice President,
Medical Affairs

[Victor M. Rivera, Ph.D.](#) Vice President,
Preclinical and
Translational Research

[William C. Shakespeare, Ph.D.](#) Vice President, Drug
Discovery

Ownership Summary

	Holders	Value (\$MM)	% O/S	Shares
Institution	12	51.13	0.0	5,705,924
Mutual Fund	8	96.10	0.0	5,647,588
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Berger (Harvey J)	4,371,103	0.0	0	05/20/16
LaMarche (Jay R)	549,526	0.0	-9,375	05/20/16
Fitzgerald (Edward M)	320,995	0.0	0	05/20/16
Wilson (Wayne)	116,125	0.0	-9,375	05/20/16
Cougar Capital LLC	115,900	0.0	5,000	12/31/16
Duvall (Martin J)	107,260	0.0	12,150	05/20/16
EverPoint Asset Management, LLC	45,000	0.0	45,000	12/31/16
DesRosier (Thomas J J.D.)	36,630	0.0	0	05/20/16
Waddell & Reed Investment Management Company	20,300	0.0	-257,700	08/31/16
Jackson Square Partners, LLC	8,885	0.0	8,885	12/31/16

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)